Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Income Before Tax

Profit after all operating and non-operating items but before income tax.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$8.02M, compared with -$12.74M a year earlier. Trailing-twelve-month income before tax was -$36.23M.

Context

  • Income before tax amounted to 2507.7% of revenue in FY2025, down 412.4 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$8.02M or moves back toward the trailing-twelve-month quarterly average of -$9.06M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.02M+11.7% QoQ
Last fiscal yearDec 2025
-$40.95M-36.4% YoY
LTMMar 2026
-$36.23M+33.6% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.1%——
1 year-36.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(40.95M) USD
Year-over-year change
-36.4%

Income Before Tax vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +33.6% is the highest of 9, against a peer median of -14.6%.
  • Income before tax amounts to 1143.2% of revenue for RANI, versus a peer median of 1764.5%.
RANI Competitors
Income Before Tax for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$36.23M USD+33.6%—1143.2%
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$40.19M USD+21.6%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$44.76M USD+8.4%—8526.1%
IPHAInnate Pharma S.A.FY2025-€49.18M EUR+0.6%—1764.5%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$68.55M USD-32.0%—3842.2%
MOLNMolecular Partners AGLTM Mar 2026-CHF 72.05M CHF-17.4%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.53M USD-68.1%——
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-$124.02M USD-55.8%—358.9%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026-$147.39M USD-11.7%—839.5%
Peer median (excluding RANI) —-14.6%—1764.5%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.72M001.03M1.63M
Cost of Revenue00822K0900K
Gross Profit2.72M0(822K)1.03M733K
Gross Margin100.0%——100.0%44.9%
Research & Development26.48M36.61M39.62M26.68M20.21M
Selling, General & Admin27.83M26.84M26.48M23.95M19.74M
Operating Expenses54.32M63.45M65.28M54.34M39.04M
Depreciation & Amortization497K548K822K1.03M900K
EBITDA(52.08M)(61.66M)(61.98M)(50.52M)(37.16M)
EBITDA Margin-1917.0%——-4914.7%-2275.5%
Operating Income(51.6M)(63.45M)(66.1M)(53.31M)(38.31M)
Operating Margin-1899.1%——-5186.2%-2346.0%
Interest Income89K1.25M3.3M1.76M827K
Interest Expense466K1.07M5.09M5.03M2.89M
Other Income / Expenses(1.45M)177K(1.78M)23.3M(2.64M)
Income Before Tax(53.05M)(63.27M)(67.88M)(30.02M)(40.95M)
Pre-Tax Margin-1952.4%——-2920.0%-2507.7%
Income Tax Expense41K70K026.57M0
Net Income(8.33M)(30.59M)(33.97M)(30.02M)(29.67M)
Net Margin-306.6%——-2920.0%-1817.1%
EPS (Basic)(0.42)(1.28)(1.33)(1.05)(0.45)
EPS (Diluted)(0.42)(1.28)(1.33)(1.05)(0.45)
Weighted Avg Shares19.53M23.82M25.51M28.48M66.14M
Weighted Avg Shares (Diluted)19.53M23.82M25.51M28.48M66.14M

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.